Kidney cancer: First-in-class HIF2α antagonist safe and effective

Kidney cancer: First-in-class HIF2α antagonist safe and effectiveKidney cancer: First-in-class HIF2α antagonist safe and effective, Published online: 16 January 2018; doi:10.1038/nrclinonc.2018.3Kidney cancer: First-in-class HIF2α antagonist safe and effective

Source: Nature Clinical Practice Oncology - January 16, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research